We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesScholar Rock Holding Corp

Scholar Rock Holding Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
44.28 USD -2.32 ( 4.98%)
Last update at 2026-11-12T15:38:00Z
VOLUME
132718
Market Cap
6089.26M

Momentum Score

…

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
43.75
Low
45.70
High
52 Week Price Range
27.07
Low
61.76
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
46.60
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-207.41M
Debt / Equity
0.44
ROE
-167.77%
Net Debt
-214.61M
ROCE
-106.36%
Diluted EPS TTM
-3.31

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -377.94M -246.29M -165.79M -134.50M -131.80M
Net income -377.94M -246.29M -165.79M -131.65M -131.80M
Selling general administrative 176.21M 67.50M 49.40M 43.12M 40.27M
Gross profit -208.44M -1.94M -2.84M 33.19M 18.82M
Reconciled depreciation 1.66M 1.94M 2.92M 2.99M 2.63M
Ebit -371.05M -239.46M -165.79M -137.36M -129.92M
Ebitda -369.39M -237.52M -162.94M -134.37M -127.29M
Depreciation and amortization 1.66M 1.94M 2.84M 2.99M 2.63M
Non operating income net other - - - -0.13M -1.88M
Operating income -384.64M -252.05M -171.29M -134.37M -129.92M
Other operating expenses 384.64M 252.05M 171.29M 167.56M 148.74M
Interest expense 6.89M 6.84M - -2.85M 1.88M
Interest income 13.90M 12.68M - - -
Net interest income 7.01M 5.84M - - -
Income tax expense - - 2.68M -2.85M 1.88M
Total revenue 0.00M 0.00M 0.00M 33.19M 18.82M
Total operating expenses 176.21M 250.12M 168.45M 167.56M 148.74M
Cost of revenue 208.44M 1.94M 2.84M - -
Total other income expense net 6.71M 5.76M 5.51M -0.13M -1.88M
Net income from continuing ops -377.94M -246.29M -158.92M -134.50M -131.80M
Net income applicable to common shares - - - -134.50M -131.80M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 404.27M 474.92M 311.04M 358.17M 304.44M
Intangible assets - 2.40M - - -
Other current assets 17.58M 11.74M 7.18M 12.66M 12.32M
Total liab 158.78M 106.29M 85.82M 97.93M 132.37M
Total stockholder equity 245.49M 368.63M 225.22M 260.24M 172.07M
Other current liab 39.57M 31.07M 20.53M 24.54M 17.69M
Common stock 0.11M 0.09M 0.08M 0.05M 0.04M
Capital stock 0.11M 0.09M 0.08M 0.05M 0.04M
Retained earnings -1300.65M -922.72M -676.42M -510.63M -376.13M
Other assets - - - 4.22M 343.57M
Cash 323.53M 177.88M 101.86M 103.28M 212.84M
Total current liabilities 55.42M 46.94M 32.74M 36.39M 64.30M
Current deferred revenue - - - - 33.19M
Net debt -214.61M -112.75M -40.04M -33.88M -135.78M
Short term debt 5.55M 5.77M 8.74M 7.85M 8.98M
Short long term debt - - 1.33M - 1.58M
Short long term debt total 108.92M 65.13M 61.82M 69.40M 77.06M
Other stockholder equity 1545.94M 1291.10M 901.47M 771.70M 548.20M
Property plant equipment - - - 7.38M 9.56M
Total current assets 385.15M 451.17M 288.19M 328.02M 265.32M
Net tangible assets - - - 260.24M 172.07M
Short term investments 44.04M 259.40M 178.08M 212.09M 40.16M
Net receivables - 2.15M 1.08M - -
Long term debt 99.71M 50.15M 48.68M 49.74M 48.42M
Accounts payable 10.30M 10.10M 3.46M 3.99M 4.43M
Accumulated other comprehensive income 0.09M 0.16M 0.09M -0.88M -0.04M
Common stock total equity - - - 0.05M 0.04M
Retained earnings total equity - - - -510.63M -376.13M
Non currrent assets other 7.04M 2.96M 4.42M 4.22M 4.12M
Non current assets total 19.12M 23.76M 22.84M 30.14M 39.13M
Capital lease obligations 9.21M 14.98M 11.80M 19.65M 27.06M
Long term debt total - - - 49.74M 48.42M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 219.29M -76.06M 66.35M -170.63M 139.56M
Change to liabilities - - - 6.63M 4.91M
Total cashflows from investing activities 218.69M -76.06M 41.14M -171.70M 134.31M
Net borrowings 49.14M 0.00M 0.00M -0.97M 24.98M
Total cash from financing activities 228.40M 353.03M 102.57M 194.83M 44.95M
Change to operating activities - - - -0.94M -10.64M
Net income -377.94M -246.29M -165.79M -134.50M -131.80M
Change in cash 147.05M 76.02M -1.51M -109.56M 52.48M
Begin period cash flow 180.28M 104.26M 105.77M 215.33M 162.86M
End period cash flow 327.33M 180.28M 104.26M 105.77M 215.33M
Total cash from operating activities -300.04M -200.95M -145.23M -132.69M -126.79M
Issuance of capital stock 91.66M 324.41M 5.22M 195.31M 13.10M
Depreciation 1.66M 1.94M 2.84M 2.99M 2.63M
Other cashflows from investing activities - - 0.01M - -
Change to account receivables - - - - 0.00M
Sale purchase of stock - - - 195.81M 19.99M
Other cashflows from financing activities 228.40M 28.61M 4.87M 0.49M 31.86M
Change to netincome - - - 27.73M 23.17M
Capital expenditures 0.60M 0.10M 0.07M 1.06M 5.25M
Cash flows other operating - - - -34.12M -26.95M
Cash and cash equivalents changes - - - -109.56M 52.48M
Change in working capital -1.05M 6.59M -10.61M -34.39M -28.44M
Stock based compensation 75.60M 36.63M 27.14M 27.70M 23.15M
Other non cash items 1.70M 0.19M 1.19M 5.51M 6.73M
Free cash flow -300.64M -201.05M -145.30M -133.76M -132.04M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SRRK
Scholar Rock Holding Corp		 -2.32
4.98%		 44.28 - - 13.14 24.88 8.22 -2.08
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Scholar Rock Holding Corp

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

301 Binney Street, Cambridge, MA, United States, 02142

857 259 3860

https://www.scholarrock.com

289

Name Title Year Born
Mr. Edward H. Myles M.B.A., MBA CFO, COO & Treasurer 1972
Dr. Jay T. Backstrom M.D., M.P.H. Pres, CEO & Director 1955
Ms. Catherine Hu VP of Investor Relations & Corp. Communications NA
Ms. Junlin Ho J.D. Gen. Counsel & Corp. Sec. 1979
Ms. Caryn Parlavecchio Chief HR Officer 1972
Ms. Lisa Amaya Price Sr. VP of HR NA
Dr. George G. Nomikos M.D., Ph.D. Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic Area NA
Ms. Erin Moore Sr. VP of Fin. 1975
Mr. Ryan Iarrobino Sr. VP of Clinical Devel. & Operations NA
Dr. Jing L. Marantz M.B.A., M.D., Ph.D. Chief Medical Officer 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…